Literature DB >> 20622117

Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.

Sydney X Lu1, Amanda M Holland, Il-Kang Na, Theis H Terwey, Onder Alpdogan, Jhoanne L Bautista, Odette M Smith, David Suh, Christopher King, Adam Kochman, Vanessa M Hubbard, Uttam K Rao, Nury Yim, Chen Liu, Alvaro C Laga, George Murphy, Robert R Jenq, Johannes L Zakrzewski, Olaf Penack, Lindsay Dykstra, Kevin Bampoe, Lia Perez, Bruce Furie, Barbara Furie, Marcel R M van den Brink.   

Abstract

Alloreactive T cells are crucial for graft-versus-host disease (GVHD) pathophysiology, and modulating their trafficking patterns has been efficacious in ameliorating experimental disease. We report in this paper that P-selectin, a glycoprotein found on resting and inflamed endothelium, is important for donor alloreactive T cells trafficking into GVHD target organs, such as the intestines and skin. Compared with wild-type (WT) recipients of allogeneic bone marrow transplantation, P-selectin(-/-) recipients exhibit decreased GVHD mortality and decreased GVHD of the skin, liver, and small bowels. This was associated with diminished infiltration of alloactivated T cells into the Peyer's patches and small bowels, coupled with increased numbers of donor T cells in the spleen and secondary lymphoid organs (SLOs). Surprisingly, however, donor T cells deficient for P-selectin glycoprotein ligand 1, the most well described P-selectin ligand, mediated GVHD similar to WT T cells and accumulated in SLO and target organs in similar numbers as WT T cells. This suggests that P-selectin may be required for trafficking into inflamed tissues but not SLO and that donor T cells may use multiple P-selectin ligands apart from P-selectin glycoprotein ligand 1 to interact with P-selectin and traffic into inflamed tissues during GVHD. We conclude that targeting P-selectin may be a viable strategy for GVHD prophylaxis or treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622117      PMCID: PMC3752704          DOI: 10.4049/jimmunol.0903148

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Endothelial ligands for L-selectin: from lymphocyte recirculation to allograft rejection.

Authors:  S D Rosen
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics.

Authors:  Shannon K Bromley; Seddon Y Thomas; Andrew D Luster
Journal:  Nat Immunol       Date:  2005-08-14       Impact factor: 25.606

3.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

Authors:  Elisha Waldman; Sydney X Lu; Vanessa M Hubbard; Adam A Kochman; Jeffrey M Eng; Theis H Terwey; Stephanie J Muriglan; Theo D Kim; Glenn Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

4.  CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses.

Authors:  Rosa Varona; Vanesa Cadenas; Lucio Gómez; Carlos Martínez-A; Gabriel Márquez
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

5.  T-cell P/E-selectin ligand alpha(1,3)fucosylation is not required for graft-vs-host disease induction.

Authors:  Hyeon-Seok Eom; Marie-Therese Rubio; Terry K Means; Andrew D Luster; Megan Sykes
Journal:  Exp Hematol       Date:  2005-12       Impact factor: 3.084

Review 6.  Structure and function of the selectin ligand PSGL-1.

Authors:  R D Cummings
Journal:  Braz J Med Biol Res       Date:  1999-05       Impact factor: 2.590

7.  CCR2 is required for CD8-induced graft-versus-host disease.

Authors:  Theis H Terwey; Theo D Kim; Adam A Kochman; Vanessa M Hubbard; Sydney Lu; Johannes L Zakrzewski; Teresa Ramirez-Montagut; Jeffrey M Eng; Stephanie J Muriglan; Glenn Heller; George F Murphy; Chen Liu; Tulin Budak-Alpdogan; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

8.  L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease.

Authors:  Suparna Dutt; Joerg Ermann; Diane Tseng; Yin Ping Liu; Tracy I George; C Garrison Fathman; Samuel Strober
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

9.  Short-term homing assay reveals a critical role for lymphocyte function-associated antigen-1 in the hepatic recruitment of lymphocytes in graft-versus-host disease.

Authors:  Tohru Sato; Aida Habtezion; Andreas Beilhack; Stephan Schulz; Eugene Butcher; Henrik Thorlacius
Journal:  J Hepatol       Date:  2005-12-27       Impact factor: 25.083

10.  TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease.

Authors:  Riham El-Asady; Rongwen Yuan; Kechang Liu; Donghua Wang; Ronald E Gress; Philip J Lucas; Cinthia B Drachenberg; Gregg A Hadley
Journal:  J Exp Med       Date:  2005-05-16       Impact factor: 14.307

View more
  12 in total

1.  Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo.

Authors:  N M Valenzuela; L Hong; X-Da Shen; F Gao; S H Young; E Rozengurt; J W Kupiec-Weglinski; M C Fishbein; E F Reed
Journal:  Am J Transplant       Date:  2012-12-27       Impact factor: 8.086

2.  Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rγ-/- mice: a promising model for studying human disease.

Authors:  Danieli Andrade; Patricia B Redecha; Milena Vukelic; Xiaoping Qing; Giorgio Perino; Jane E Salmon; Gloria C Koo
Journal:  Arthritis Rheum       Date:  2011-09

3.  Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Authors:  Ran Reshef; Alex Ganetsky; Edward P Acosta; Robin Blauser; Lisa Crisalli; Jessica McGraw; Noelle V Frey; Elizabeth O Hexner; James A Hoxie; Alison W Loren; Selina M Luger; James Mangan; Edward A Stadtmauer; Rosemarie Mick; Robert H Vonderheide; David L Porter
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-10       Impact factor: 5.742

4.  Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation.

Authors:  Hung D Nguyen; Shilpak Chatterjee; Kelley M K Haarberg; Yongxia Wu; David Bastian; Jessica Heinrichs; Jianing Fu; Anusara Daenthanasanmak; Steven Schutt; Sharad Shrestha; Chen Liu; Honglin Wang; Hongbo Chi; Shikhar Mehrotra; Xue-Zhong Yu
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

5.  GCNT1-Mediated O-Glycosylation of the Sialomucin CD43 Is a Sensitive Indicator of Notch Signaling in Activated T Cells.

Authors:  Eric Perkey; Dave Maurice De Sousa; Léolène Carrington; Jooho Chung; Alexander Dils; David Granadier; Ute Koch; Freddy Radtke; Burkhard Ludewig; Bruce R Blazar; Christian W Siebel; Todd V Brennan; Jeffrey Nolz; Nathalie Labrecque; Ivan Maillard
Journal:  J Immunol       Date:  2020-02-14       Impact factor: 5.422

6.  PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD.

Authors:  Arnab Ghosh; Amanda M Holland; Yildirim Dogan; Nury L Yim; Uttam K Rao; Lauren F Young; Mallory L West; Natalie V Singer; Hae Lee; Il-Kang Na; Jennifer J Tsai; Robert R Jenq; Olaf Penack; Alan M Hanash; Cecilia Lezcano; George F Murphy; Chen Liu; Michel Sadelain; Martin G Sauer; Derek Sant'angelo; Marcel R M van den Brink
Journal:  Cancer Res       Date:  2013-06-03       Impact factor: 12.701

7.  In vivo administration of recombinant BTNL2-Fc fusion protein ameliorates graft-versus-host disease in mice.

Authors:  Cheng Cui; Xiaohong Tian; Yujun Lin; Min Su; Qingquan Chen; Shao-Yuan Wang; Laijun Lai
Journal:  Cell Immunol       Date:  2018-10-26       Impact factor: 4.868

Review 8.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

9.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

10.  A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model.

Authors:  Carina A Bäuerlein; Simone S Riedel; Jeanette Baker; Christian Brede; Ana-Laura Jordán Garrote; Martin Chopra; Miriam Ritz; Georg F Beilhack; Stephan Schulz; Robert Zeiser; Paul G Schlegel; Hermann Einsele; Robert S Negrin; Andreas Beilhack
Journal:  BMC Med       Date:  2013-05-21       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.